← Patent-cliff monitor small molecule ZYNRELEF KIT BUPIVACAINE; MELOXICAM
Loss of exclusivity April 2036 latest FDA-listed patent expiry
Drug detail Brand name ZYNRELEF KIT Active ingredient BUPIVACAINE; MELOXICAM Strength 200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) Dosage form SOLUTION, EXTENDED RELEASE Route PERIARTICULAR Modality Small molecule FDA approval May 2021 Marketing status RX
Listed patents Patent Expires Type 11844837 April 2036 use U-3417 9694079 April 2035 product 9801945 April 2035 product 10213510 April 2035 product 11413350 April 2035 use U-3417 10632199 April 2035 product 10898575 April 2035 product 11083797 April 2035 product 11083730 April 2035 product 10980886 April 2035 product 10098957 April 2035 use U-3118 9913909 March 2034 use U-3118 11253504 March 2034 use U-3118 9592227 March 2034 product 10398686 March 2034 product 9744163 March 2034 product
Regulatory exclusivity Code Expires I-933 January 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.